Posted by Michael Wonder on 02 Aug 2017
Roche invited to submit a CDF proposal for urothelial cancer drug
2 August 2017 - NICE has asked Roche to submit a Cancer Drugs Fund proposal for an immunotherapy treatment called atezolizumab.
Atezolizumab (marketed as Tecentriq) was assessed by NICE as a treatment for people who have advanced urothelial cancer.
The NICE committee found stronger evidence is needed to show the drug is both clinically and cost effective.
Therefore, they are inviting Roche to submit a Cancer Drug Fund proposal for atezolizumab.
